Risk of Coccidioidomycosis in Patients Receiving Anti-TNF and Other Biologic Agents for an Inflammatory Arthritis

Completed

• Conditions: Coccidioidomycosis; Rheumatoid Arthritis

• Registration Number: NCT00796809
• Lead Sponsor: University of Arizona

Brief Summary

The goal of the project is to study the risk of coccidioidomycosis (valley fever) in patients receiving anti-TNF and other biologic agents for inflammatory arthritis in Tucson, Arizona.

Detailed Description

Retrospective chart review of all patients with an inflammatory arthritis seen at the University Rheumatology clinic since January 2000.

Study Timeline

• Study Start: 2007-10
• Primary Completion: 2008-06
• Study Completion: 2008-10
• Study First Submitted: 2008-11-21
• Study First Submitted QC: 2008-11-21
• Study First Posted: 2008-11-24
• Status Verified: 2015-12
• Last Update Submitted: 2015-12-11
• Last Update Posted: 2015-12-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 598

Inclusion Criteria

• All active patients with an inflammatory arthritis seen at the University of Arizona from January 2000

Exclusion Criteria

• None

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Determine the incidence rate and calculate the risk of coccidioidomycosis in patients receiving various anti-TNF agents or other biologics, and patients not receiving these agents for their inflammatory arthritis	one year

Secondary Outcome Measures

Name	Time	Method
To compare number of disseminated cases of coccidioidomycosis in each group	One year
To calculate the incidence density of coccidioidomycosis cases in patients receiving each drug.	One year

Trial Locations

Locations (1)

University of Arizona - Arizona Arthritis Center; 🇺🇸 Tucson, Arizona, United States